These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 24503176

  • 1. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 2. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
    Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, Zhao J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul 13; 85():69-76. PubMed ID: 29678772
    [Abstract] [Full Text] [Related]

  • 3. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
    Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, Rezaei Z.
    Recent Pat Inflamm Allergy Drug Discov; 2014 Jul 13; 8(3):211-5. PubMed ID: 25353174
    [Abstract] [Full Text] [Related]

  • 4. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS.
    J Clin Psychiatry; 2010 Nov 13; 71(11):1475-81. PubMed ID: 20816042
    [Abstract] [Full Text] [Related]

  • 5. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun 13; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 6. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M.
    J Clin Psychiatry; 2012 Sep 13; 73(9):e1168-74. PubMed ID: 23059159
    [Abstract] [Full Text] [Related]

  • 7. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec 13; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 8. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct 13; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 9. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
    Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH, Lee SH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan 15; 35(1):208-11. PubMed ID: 21095214
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 15; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 11. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb 15; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 12. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM, Yang R, Youakim JM.
    Schizophr Res; 2012 Mar 15; 135(1-3):116-22. PubMed ID: 22178084
    [Abstract] [Full Text] [Related]

  • 13. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
    Vayısoğlu S, Anıl Yağcıoğlu AE, Yağcıoğlu S, Karahan S, Karcı O, Gürel SC, Yazıcı MK.
    Schizophr Res; 2013 Jan 15; 143(1):207-14. PubMed ID: 23217729
    [Abstract] [Full Text] [Related]

  • 14. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA.
    Neuropsychopharmacology; 2008 Feb 15; 33(3):465-72. PubMed ID: 17487227
    [Abstract] [Full Text] [Related]

  • 15. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.
    Arch Gen Psychiatry; 2005 Nov 15; 62(11):1196-204. PubMed ID: 16275807
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG.
    Schizophr Res; 2013 Apr 15; 145(1-3):101-9. PubMed ID: 23415311
    [Abstract] [Full Text] [Related]

  • 17. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S.
    Psychiatry Res; 2014 Mar 30; 215(3):540-6. PubMed ID: 24480077
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.
    Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S.
    J Clin Psychiatry; 2010 Feb 30; 71(2):138-49. PubMed ID: 19895780
    [Abstract] [Full Text] [Related]

  • 19. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
    Weiser M, Levi L, Burshtein S, Chiriță R, Cirjaliu D, Gonen I, Yolken R, Davidson M, Zamora D, Davis JM.
    Schizophr Res; 2019 Apr 30; 206():325-332. PubMed ID: 30455075
    [Abstract] [Full Text] [Related]

  • 20. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.
    J Clin Psychiatry; 2006 Dec 30; 67(12):1912-9. PubMed ID: 17194269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.